IFN-β liquid formulations
AssigneeApplied Research Systems ARS Holding N.V.
InventorsFabrizio Samaritani, Patrizia Natale
Life of this patent
Estimating the term…
Abstract
Interferon-beta liquid formulations stabilized with a polyol, a non-reducing sugar or a amino acid. In particular, the formulations are stabilized with a polyol, such as mannitol. The formulations, preferably, furthermore comprise a buffer, such as acetate buffer, at a pH comprised between 3.0 and 4.0 and human albumin at a minimum quantity. The interferon-beta is preferably recombinant.
Claims6
A liquid pharmaceutical formulation consisting essentially of 1 MIU/ml of recombinant interferon-beta, 54.6 mg/ml of a stabilising agent which is mannitol, 0.5 mg/ml of human albumin in a solution of 0.01 M citrate buffer at pH 3.
A liquid pharmaceutical formulation consisting of 1 MIU/ml of recombinant interferon-beta, 54.6 mg/ml of a stabilizing agent which is mannitol, 0.5 mg/ml of human albumin in a solution of 0.01 M citrate buffer at pH 3.
Dependencies are inferred from the claim text.